27-Mar-2026
PRNewswire (Fri, 27-Feb 7:00 AM ET)
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
PRNewswire (Tue, 24-Feb 4:05 PM ET)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Fri, 20-Feb 4:05 PM ET)
TransMedics to Present at Upcoming March Investor Conferences
PRNewswire (Tue, 17-Feb 4:05 PM ET)
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
PRNewswire (Tue, 10-Feb 4:05 PM ET)
Market Chameleon (Mon, 9-Feb 4:02 AM ET)
PRNewswire (Mon, 9-Feb 8:00 AM ET)
PRNewswire (Mon, 12-Jan 8:10 AM ET)
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Tue, 30-Dec 4:05 PM ET)
Market Chameleon (Mon, 3-Nov 3:28 AM ET)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Transmedics Group trades on the NASDAQ stock market under the symbol TMDX.
As of March 27, 2026, TMDX stock price declined to $99.05 with 764,303 million shares trading.
TMDX has a beta of 1.23, meaning it tends to be more sensitive to market movements. TMDX has a correlation of 0.12 to the broad based SPY ETF.
TMDX has a market cap of $3.38 billion. This is considered a Mid Cap stock.
Last quarter Transmedics Group reported $161 million in Revenue and $.57 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.18.
In the last 3 years, TMDX traded as high as $177.37 and as low as $36.42.
The top ETF exchange traded funds that TMDX belongs to (by Net Assets): IJR, VTI, VB, IWM, VBK.
TMDX has outperformed the market in the last year with a return of +40.6%, while the SPY ETF gained +13.1%. However, in the most recent history, TMDX shares have underperformed the stock market with its stock returning -20.2% in the last 3 month period and -19.8% for the last 2 week period, while SPY has returned -7.9% and -4.0%, respectively.
TMDX support price is $97.45 and resistance is $106.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TMDX shares will trade within this expected range on the day.